The UK and US have agreed to a key trade agreement that will ensure no duties on UK pharmaceutical exports being sold in the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to raise spending on medicines through the NHS. This commitment secures that import taxes on these vital products will be held at zero for a timeframe of three years.
This development follows earlier threats to hike import taxes on branded drug products, with increases mentioned up to one hundred percent.
"This agreement between the Britain strengthens the worldwide climate for innovative medicines and brings long-overdue balance to American-British medicine commerce," an announcement said.
Commercial Importance
Drugs represent one of the Britain's most significant exports to the US, which is easily the primary buyer for major British pharmaceutical firms.
Export figures show that in the year leading up to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This value made up a significant portion of all goods exports in that period.
"This guarantee secures jobs, boosts investment and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement involves several notable pledges from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates were more than 20%.
Industry Background
This agreement comes amid a ongoing row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were intensified by assertions that US patients were paying a premium for the identical medicines than consumers in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
